-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 17, Hisco announced that it had recently received the "Notice of Acceptance" issued by the State Drug Administration, and that HSK36273 for injection was approved for clinical trials
HSK36273 for injection is an intravenous anticoagulant drug EP-7041 introduced by Haisco in the early stage.
Hemodialysis is one of the treatments for acute and chronic renal failure
At present, the drugs commonly used in clinical anticoagulation therapy mainly include vitamin K antagonists, heparin, small molecule heparin, coagulation factor Xa inhibitors, direct thrombin inhibitors and thrombolytics
HSK36273 is a novel anticoagulant drug that only acts on the intrinsic coagulation pathway, and is expected to solve the bleeding problem in clinical anticoagulation therapy